Cargando…

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

INTRODUCTION: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). METHODS: The PROTECT tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barratt, Jonathan, Rovin, Brad, Wong, Muh Geot, Alpers, Charles E., Bieler, Stewart, He, Ping, Inrig, Jula, Komers, Radko, Heerspink, Hiddo J.L., Mercer, Alex, Noronha, Irene L., Radhakrishnan, Jai, Rheault, Michelle N., Rote, William, Trachtman, Howard, Trimarchi, Hernán, Perkovic, Vlado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166729/ https://www.ncbi.nlm.nih.gov/pubmed/37180506 http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Ejemplares similares

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
por: Komers, Radko, et al.
Publicado: (2020)

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
por: Trachtman, Howard, et al.
Publicado: (2023)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
por: Barratt, Jonathan, et al.
Publicado: (2019)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
por: Komers, Radko, et al.
Publicado: (2017)

Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Maximizing the value of the open label extension phase of randomized clinical trials
por: Trachtman, Howard, et al.
Publicado: (2023)

Correction to: Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis
por: Liyanage, Thaminda, et al.
Publicado: (2016)

Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis
por: Wada, Russell, et al.
Publicado: (2023)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

Why Target the Gut to Treat IgA Nephropathy?
por: Barratt, Jonathan, et al.
Publicado: (2020)

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
por: Komers, Radko, et al.
Publicado: (2016)

Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis
por: Sukkar, Louisa, et al.
Publicado: (2016)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor
por: Oshima, Megumi, et al.
Publicado: (2020)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Biomarkers in kidney fibrosis: are they useful?
por: Wong, Muh Geot, et al.
Publicado: (2014)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
por: Floege, Jürgen, et al.
Publicado: (2022)

Microplate-based platform for combined chromatin and DNA methylation immunoprecipitation assays
por: Yu, Jingjing, et al.
Publicado: (2011)

The Evidence for Sparsentan-Mediated Inhibition of I(Na) and I(K(erg)): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor
por: Chuang, Tzu-Hsien, et al.
Publicado: (2021)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Baseline characteristics and enrichment results from the SONAR trial
por: Heerspink, Hiddo J.L., et al.
Publicado: (2018)

New hypoglycemic agents and the kidney: what do the major trials tell us?
por: Smyth, Brendan, et al.
Publicado: (2018)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program
por: Young, Tamara K., et al.
Publicado: (2021)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
por: Tuttle, Katherine R., et al.
Publicado: (2021)

Blood pressure: at what level is treatment worthwhile?
por: Atkins, Emily R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fvfqic2g747heht3n8js70bqtf